Edan Instruments overhauls governance, reports strong Q3 growth

Edan Instruments Inc. achieved a 15.72% increase in Q3 2025 revenue to 532,269,656.86 yuan and a 118.28% rise in net profit to 102,174,097.17 yuan, attributed to growth in international markets and increased R&D. Year-to-date revenue reached 1,446,076,915.63 yuan, up 4.63%, with net profit increasing 49.29% to 256,625,532.09 yuan. Key balance sheet changes include a 61.22% increase in accounts receivable due to international sales and a 35.70% rise in construction in progress from the expansion of its industrial park.

The company announced a major overhaul of its corporate governance, including the dissolution of the Supervisory Board, with its functions transferred to the Audit Committee. This restructuring necessitates revisions to the Company Articles of Association, along with new and updated governance policies, including those for external investments, related party transactions, and information disclosure. These changes will take effect after shareholder approval.

Strategic initiatives include significant progress in its US manufacturing project, with a new facility in San Diego receiving MDSAP certification and FDB medical device manufacturing licenses in July 2025. Additionally, Edan continues to collaborate with Global Health Labs, Inc. on a handheld ultrasound device project, securing a $2.65 million grant from the Gates Foundation for clinical trials and market introduction. These efforts underscore Edan's commitment to innovation and global expansion.